New Research Links Cannabis Use to Increased Cardiovascular Risk
Cannabis consumption might significantly elevate the odds of dying from heart disease—up to double the risk—and raises the likelihood of a stroke by about 20%, as indicated by a recent comprehensive review of global data.
Over the last ten years, the number of cannabis and cannabinoid users has surged, and while there’s been previous research associating cannabis use with heart issues, the extent of that risk wasn’t fully understood—until now.
This gap in knowledge seems vital, especially given the shifts in consumption patterns, according to researchers from the University of Toulouse in France.
To enhance the existing body of evidence, they meticulously examined databases for extensive observational studies published between 2016 and 2023 that investigated the relationship between cannabis use and cardiovascular health outcomes.
A total of 24 studies, encompassing around 200 million individuals, were included in their analysis. It comprised 17 cross-sectional studies, six cohort studies, and one case-control study.
Most participants were aged between 19 and 59, and where gender was noted, it appeared that cannabis users tended to be predominantly younger males compared to non-users.
The pooled analysis identified several increased risks associated with cannabis: a 29% higher likelihood of acute coronary syndrome, a 20% increase in stroke risk, and importantly, a doubled risk of death from cardiovascular diseases. These findings were published in the journal Heart.
The researchers did note several limitations in their review, including a moderate to high risk of bias in many of the studies. This was primarily due to issues related to missing data and insufficient measures of cannabis exposure, given that most were observational studies utilizing similar datasets.
Despite these limitations, the researchers believe their work provides a thorough examination of the potential connection between cannabis use and significant cardiovascular issues, shedding new light on real-world implications. They stated, “The findings outlined by this meta-analysis should enhance general awareness of the potential hazards cannabis poses to cardiovascular health.”
In a related commentary, Prof Stanton Glantz and Dr. Lynn Silver from the University of California at San Francisco pointed out that the analysis “raises serious questions about the assumption that cannabis imposes little cardiovascular risk.” They emphasized the need for further research to determine whether the cardiovascular risks are confined to inhaled products or also pertain to other forms of cannabis usage.
Interestingly, they noted that cannabis has become generally more potent and now comes in a variety of forms, including high-potency concentrates and edibles. They remarked, “How these changes affect cardiovascular risk needs clarification, as does the proportion of risk linked to cannabinoids versus other components in cannabis.”
Moreover, they proposed that cannabis should be regarded through a lens similar to tobacco: decriminalized yet discouraged, while ensuring bystanders are protected from secondhand exposure. They argue that effective warnings about risks need to be developed and enforced as the evidence surrounding cannabis consumption continues to evolve.
Ultimately, they suggest that the regulation of cannabis markets should not only focus on creating a legal framework but also prioritize minimizing health risks linked to its use.
